<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166604</url>
  </required_header>
  <id_info>
    <org_study_id>LONGBOARD C19-01</org_study_id>
    <nct_id>NCT04166604</nct_id>
  </id_info>
  <brief_title>LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy</brief_title>
  <acronym>LONGBOARD</acronym>
  <official_title>LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective cohort of patients treated with trifluridine/tipiracil, maximal sample size 250
      patients. It is expected, that 89 patients will experience a grade 3-4 neutropenia and will
      be included in the phase II.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trifluridine/tipiracil has demonstrated its efficacy in patients with metastatic colorectal
      cancer (mCRC) resistant to standard drugs (fluoropyrimidine, oxaliplatin, irinotecan,
      bevacizumab, and panitumumab or cetuximab in case of RAS wild-type tumors). This treatment
      has a marketing authorization.

      Neutropenia is a classic complication of cytotoxic treatments. Febrile neutropenia are
      associated with a mortality rate of 9.5% and a hospitalization of 6 days in median. Recent
      meta-analyses have reported that the use of granulocyte-colony stimulating factor (GCSF)
      allows to maintain the dose-intensity of cytotoxic treatment and was associated with a better
      overall survival (OS).

      There is currently no clear recommendation for the use of G-CSF with trifluridine/tipiracil.

      Unpublished analyses that various clinical parameters may be associated with the risk of
      neutropenia: age ≥ 65 years, female sex, level of leukocytes at baseline, and time of initial
      diagnostic to randomization ≥ 36 months.These data are too preliminary to allow proposing a
      G-CSF primary prophylaxis in a defined subgroup of patients. However, a secondary prophylaxis
      based on the administration of G-CSF seems efficient, with a prescription from day 14 to day
      18.

      The aim of this phase II study is to assess the efficacy of the secondary prophylaxis with
      G-CSF in case of first episode of grade 3-4 neutropenia in the aim to maintain the optimal
      dose intensity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>250 patients need to be included in a prospective cohort, to obtained 89 patients in the phase II (experience a grade 3-4 neutropenia)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients free of trifluridine/tipiracil dose reduction or postponement of cycles of &gt; 7 days at 6 months or at progression or death or stop of treatment for another cause than neutropenia if observed in the 6 months.</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Overall survival (OS) is defined as the time from study enrollment to death (from any cause) or to the last date the patients was known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 30 months</time_frame>
    <description>PFS is defined as the time (in months) from study enrollment until objective PD or death from any cause. If the patient dies before reaching PD, the date of death is considered as the date that PD was reached. For patients that had not reached PD at the time of the analysis, and for patients for whom the PD date is unknown, PFS is censored at the date of patient's final assessment prior to data cut-off.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Objective response rate is defined as proportion of patients with reduction in tumor burden of predefined amount. It refers to the number of patients with CR, PR according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>The disease control rate (DCR) is defined as the proportion of patients in whom the best overall response is determined as complete response, partial response or stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Patients will be assessed for AEs throughout the study at every visit during treatment. Investigators using the NCI-CTCAE version 5.0 will grade the severity of AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with dose reductions</measure>
    <time_frame>up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polymorphisms analysis of ATM and XRCC3</measure>
    <time_frame>Blood samples at baseline and at Cycle 2 Day 1 (Day 28 of cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the level of circulating tumor DNA</measure>
    <time_frame>Blood samples at baseline and at Cycle 2 Day 1 (Day 28 of cycle 1)</time_frame>
    <description>Circulating cell-free DNA will be sequenced using the AmpliSeq Colon and Lung Cancer Panel V2 on an Ion Proton following the manufacturer's recommendations (Life Technology), and date will be analyzed using the BPER method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the level of seric growth factors TGF β</measure>
    <time_frame>Blood samples at baseline and at Cycle 2 Day 1 (Day 28 of cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the level of seric growth factors TGF α</measure>
    <time_frame>Blood samples at baseline and at Cycle 2 Day 1 (Day 28 of cycle 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>trifluridine/tipiracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35mg/m² BID (PER OS) (one cycle every 4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifluridine/Tipiracil</intervention_name>
    <description>after morning and evening meal,
Days 1 through 5: 35mg/m2 (twice daily)
Days 6 through 7: recovery
Days 8 through 12: 35mg/m2 (twice daily)
Day 13 through 28: recovery
In case of first event of grade 3-4 neutropenia : patients will not have a dose reduction and will receive a secondary prophylaxis with G-CSF (filgrastim or lenograstim) during subsequent cycle: a starting 5 mg/kg/day dose of filgrastim or lenograstim as a single daily injection, for 5 days, from day 14 to day 18
In case of secondary event of grade 3-4 neutropenia despite G-CSF secondary prophylaxis, dose adjustment of trifluridine/tipiracil will be done according to Summary of Product Characteristics (SmPC). G-CSF secondary prophylaxis will be continuing with the reduction.
dose</description>
    <arm_group_label>trifluridine/tipiracil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent,

          2. Patients willing and able to comply with protocol requirements,

          3. Histologically proven colorectal adenocarcinoma,

          4. Stage IV disease,

          5. Have life expectancy of at least 6 months,

          6. Previous chemotherapy regimens with each of the following agents: fluoropyrimidine,
             oxaliplatin, irinotecan, anti-vascular endothelial growth factor (VEGF) therapy
             (bevacizumab, aflibercept), and anti-epidermal growth factor receptor (EGFR) therapy
             (cetuximab or panitumumab for tumors with wild-type RAS and/or BRAF wild type),

          7. At least one measurable or evaluable lesion as assessed by computed tomography
             (CT)-scan or magnetic resonance imaging (MRI) according to RECIST v1.1,

          8. Age ≥ 18 years,

          9. ECOG PS 0-1,

         10. Adequate hematologic function: neutrophils &gt; 1.5 x 109 /L; platelets &gt; 100 x 109 /L;
             hemoglobin ≥ 9 g/dL,

         11. Calculated creatinine clearance ≥ 30 mL/min,

         12. Adequate liver function: aspartate aminotransferase (AST) and alanine aminotransferase
             (ALT) ≤ 2.5 x upper limit normal ULN;

             ≤ 5 x ULN in case of liver metastasis), total bilirubin ≤ 1.5 x ULN (&lt; 2 x ULN if
             hyperbilirubinemia is due to Gilbert's syndrome), albumin ≥ 25 g/L,

         13. Baseline evaluations: clinical and blood evaluations no more than 14 days prior to
             inclusion and start of trifluridine/tipiracil, Tumor assessment (CT-scan or MRI,
             evaluation of non-measurable lesions) no more than 21 days prior to inclusion and
             start of trifluridine/tipiracil,

         14. Female patients must be surgically sterile, or be postmenopausal, or must commit to
             using reliable and appropriate methods of contraception during the study (must have a
             negative pregnancy test within 7 days prior to enrollment) and during at least 6
             months after the end of the last dose of study treatment (when applicable). All female
             patients with reproductive potential must have a negative pregnancy test (β-HCG)
             within 72 hours prior to starting trifluridine/tipiracil treatment. Breastfeeding is
             not allowed. Male patients must agree to use effective contraception in addition to
             having their partner use a contraceptive method as well during the trial and during at
             least 6 months after the end of the study treatment,

         15. Registration with the French National Health Care System or PUMA (Protection
             Universelle MAladie).

        Exclusion Criteria:

          1. Medical history or evidence of CNS metastasis upon physical examination, unless
             adequately treated (e.g. non-irradiated CNS metastasis, seizure not controlled with
             standard medical therapy, patients are stable without evidence of progression for at
             least 28 days prior to the first dose of treatment),

          2. Local or locally advanced disease (stage I to III),

          3. Treatment with warfarin,

          4. Uncontrolled hypercalcemia,

          5. Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted
             therapy, immunotherapy),

          6. Known complete dihydropyrimidine dehydrogenase (DPD) deficiency,

          7. Treatment with any other investigational medicinal product within 28 days prior to
             study entry,

          8. Symptomatic carcinomatosis with occlusive symptoms or ascites requiring paracentesis,

          9. Other serious and uncontrolled non-malignant disease (e.g. active infection requiring
             systemic therapy, coronary stenting or myocardial infarction, or stroke in the past 6
             months),

         10. HIV-infected patients or otherwise known to be HIV-positive,

         11. Untreated hepatitis B or C,

         12. Other concomitant or previous malignancy, except: i/ adequately treated in-situ
             carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin,
             iii/ cancer in complete remission for &gt; 5 years,

         13. Concomitant administration of prophylactic phenytoin and live attenuated virus vaccine
             such as yellow fever vaccine 28 days prior to the first dose of treatment.

         14. Patient under guardianship, curatorship or under the protection of justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Baptiste BACHET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pitié Salpêtrière</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Line GARCIA LARNICOL</last_name>
    <phone>01 40 20 85 00</phone>
    <email>gercor@gercor.com.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent HAUTEFEUILLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent HAUTEFEUILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie VANBOCKSTAEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julie VANBOCKSTAEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano KIM, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefano KIM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>centre Pierre Curie</name>
      <address>
        <city>Beuvry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélie FADIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélie FADIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric LECAILLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cédric LECAILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Chauny</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc KANAAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marc KANAAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Sainte Côme</name>
      <address>
        <city>Compiègne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaïs ALDABBAGH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kaïs ALDABBAGH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de Flandre</name>
      <address>
        <city>Coudekerque-Branche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Philippe wagner, mD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Philippe WAGNER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle BAUMGAERTNER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle BAUMGAERTNER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila BENGRINE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leila BENGRINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margot LALY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Franco-Britannique</name>
      <address>
        <city>Levallois-Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoist CHIBAUDEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benoist CHIBAUDEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme DESRAME, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme DESRAME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves RINALDI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yves RINALDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Layne</name>
      <address>
        <city>Mont-de-Marsan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick TEXEREAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrick TEXEREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche Comté</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marine JARY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marine JARY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Sapêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Baptiste BACHET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Baptiste BACHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain CORIAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Romain CORIAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle TROUILLOUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>ISabelle TROUILLOUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis SMITH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Denis SMITH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David TOUGERON, MD</last_name>
    </contact>
    <investigator>
      <last_name>David TOUGERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier BOUCHE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier BOUCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>trifluridine/ tipiracil</keyword>
  <keyword>G-CSF</keyword>
  <keyword>neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

